scholarly journals The Effects of Topical Antiglaucoma Drugs as Monotherapy on the Ocular Surface: A Prospective Study

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Sevda Aydin Kurna ◽  
Semih Acikgoz ◽  
Ahmet Altun ◽  
Nurver Ozbay ◽  
Tomris Sengor ◽  
...  
Keyword(s):  
Prospective Study ◽  
Ocular Surface ◽  
Beta Blockers ◽  
Squamous Metaplasia ◽  
Tear Film ◽  
Eye Drops ◽  
Group 2 ◽  
A Prospective Study ◽  
Breakup Time ◽  
Corneal Staining

Purpose. The aim was to compare the effects of antiglaucoma eye drops on the tear functions and ocular surface.Method. Eighty-five eyes of 43 patients with glaucoma were included into this randomized prospective study. Timolol without preservative (1), timolol with benzododecinium bromide (2), latanoprost (3), bimatoprost (4), travoprost with benzalkonium chloride (5), and brimonidine with purite (6) were given to 6 groups. Schirmer I, tear film breakup time (TBUT), staining scores, and impression cytology samples were evaluated before and during 12-month-follow-up period.Results. At the end of 12 months, there was no detected change in Schirmer I and TBUT tests indicating dry eye. Corneal staining scores were higher in groups 1 and 2, while conjunctival staining scores were higher in group 6. Goblet cell count decreased in groups 1 and 5 in superior and inferior, group 2 in superior, and groups 3 and 6 in inferior conjunctiva. Squamous metaplasia grades showed a significant increase in groups 1 and 2 at 3rd, 6th, and 12th month controls (P<0.05).Conclusion. We observed nonserious impact on tear functions and ocular surface with antiglaucoma monotherapy. Beta blockers induced more damage on the ocular surface suggesting the role of the dosing and active substances beside preservatives.

scholarly journals The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (Sod1) Knockout Mice Treated with Antiglaucoma Eye Medications

Diagnostics ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 20 ◽  
Author(s):  
Yukari Yagi-Yaguchi ◽  
Takashi Kojima ◽  
Kazunari Higa ◽  
Murat Dogru ◽  
Osama MA. Ibrahim ◽  
...  
Keyword(s):  
Ocular Surface ◽  
Vital Staining ◽  
Goblet Cells ◽  
Surface Epithelium ◽  
Control Group ◽  
Eye Drops ◽  
Group 4 ◽  
Group 2 ◽  
Corneal Staining ◽  
Group 1

Anti-glaucoma eye drop treatment often induces dry eyes and can lead to poor medication adherence. This study aimed to investigate the effects of 3% diquafosol sodium eye drops on tear function and the ocular surface epithelium in Sod1−/− mice after treatment with anti-glaucoma eye drops. The mice were divided into four groups: group 1, control group; group 2, anti-glaucoma eye drop; group 3, anti-glaucoma eye drops followed by a secretagogue eye drop (3% diquafosol); and group 4, simultaneous anti-glaucoma and secretagogue eye drop. Mice underwent assessments of tear quantity, tear film breakup time, and vital staining score. Mice in groups 3 and 4 showed significantly better tear stability and lower corneal staining scores than mice in group 2 after eye drop instillations (p < 0.05). Mice in group 4 showed significantly better tear stability, lower corneal staining scores, and higher goblet cell densities than those in group 1 after eye drop instillations (p < 0.05). The conjunctival epithelium showed stratification and abundance of Muc5AC-positive goblet cells in group 4, whereas thinning with desquamation was observed with a few goblet cells in group 2. Thus, simultaneous administration of 3% diquafosol sodium eye drops with topical anti-glaucoma drops showed favorable effects on tear stability and the corneal epithelium against the ocular surface toxicity inflicted by the anti-glaucoma eye drops.

scholarly journals A comparative study of efficacy of chloroquine phosphate 0.03% and sodium carboxymethylcellulose 1% in dry eye

2021 ◽  
Vol 7 (2) ◽  
pp. 302-307
Author(s):  
Vandana Sharma ◽  
Parag Tyagi ◽  
J P Chugh ◽  
R S Chauhan ◽  
Ashok Rathi
Keyword(s):  
Drug Therapy ◽  
Comparative Study ◽  
Dry Eye ◽  
Ocular Surface ◽  
Tear Film ◽  
Eye Drops ◽  
Onset Of Action ◽  
Dry Eyes ◽  
Ocular Symptoms ◽  
Group 2

Dry eye disease (DED) is a multifactorial disease of the tear film which leads to ocular discomfort, visual disturbances and damage to ocular surface. The objective of treatment of DED has now shifted from managemnt of ocular symptoms and patient relief to attainment of normal physiological composition of the tear film.Aim of this study was to compare the efficacy of chloroquine phosphate 0.03% (CQP) eye drops with sodium carboxymethyl cellulose 1% (CMC) eye drops in the management of DED. A single blind, prospective and comparative study including 100 patients of dry eyes was planned. The patients were randomly divided into two groups, each comprising of 50 patients. Group-1 patients were given CMC 1% eye drops 4 times a day for 12 weeks and Group-2 patients were given CQP 0.03% eye drops as the treatment modality 2 times a day for 12 weeks. The efficacy of both the drugs was compared and evaluated statistically. The study showed that both CQP and CMC eye drops are effective in treating DED, although faster onset of action was observed with CQP on ocular surface staining tests and Schirmer’s test. Also, it was noted that patients with severe DED showed least improvement in both the groups suggesting that mono-drug therapy is least effective in treatment of severe DED and multi drug therapy should be used early in treatment of severe DED.

Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases

2018 ◽  
Vol 30 (1) ◽  
pp. 94-103 ◽  
Author(s):  
Ronald M Sanchez-Avila ◽  
Jesus Merayo-Lloves ◽  
Francisco Muruzabal ◽  
Gorka Orive ◽  
Eduardo Anitua
Keyword(s):  
Growth Factors ◽  
Graft Versus Host Disease ◽  
Ocular Surface ◽  
Tear Film ◽  
Visual Analog Score ◽  
Eye Drops ◽  
Ocular Surface Disease Index ◽  
Host Disease ◽  
Graft Versus Host ◽  
Breakup Time

Purpose: To evaluate the efficacy and safety of plasma rich in growth factors eye drops for the treatment of corneal and ocular surface disorders in patients with graft versus host disease. Methods: This retrospective and longitudinal study included graft versus host disease patients with ocular disorders. The resolution of corneal ulcers (area and density staining) was evaluated as primary outcome. Best corrected visual acuity, intraocular pressure, tear film breakup time, Schirmer test, ocular surface disease index, and visual analog score were evaluated as secondary outcomes. All variables were analyzed before and after plasma rich in growth factors treatment. The safety of plasma rich in growth factors treatment was also assessed. Results: Twelve patients (23 eyes) with ocular graft versus host disease were evaluated. Statistically significant improvement in the area (75.7%) and density (73.3%) of the corneal staining, in best corrected visual acuity (74.7%), in ocular surface disease index scale (75.4%), visual analog score frequency (81.4%) and visual analog score severity (81.9%), and an increase of 3.8 s in tear film breakup time and 6 mm in Schirmer test was observed after plasma rich in growth factors treatment (p < 0.001). Some potential modifiers of the therapeutic effect were identified. All patients achieved corneal stability without perforation risk. No adverse events associated with the plasma rich in growth factors were observed. Conclusion: Immunosafe plasma rich in growth factors eye drops for the treatment of patients with ocular graft versus host disease could be safe and effective, showing a high rate of corneal ulcer resolution and dry eye disease control. Plasma rich in growth factors eye drops may help to maintain corneal stability and prevent it against higher ocular complications.

scholarly journals Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Miraf Sahlu ◽  
Abeba T. Giorgis
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Signs And Symptoms ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Schirmer Test ◽  
Ocular Surface Disease Index ◽  
Cross Sectional ◽  
Corneal Staining

Abstract Background Dry eye disease is a multifactorial disease; causing various ocular symptoms with potential damage to the ocular surface. Applying hypotensive eye drops are presumed to initiate or exacerbate existing dry eye disease. The purpose of this study was to determine the frequency of signs and symptoms and severity of dry eye disease among glaucoma patients on topical hypotensive medications and controls. Methods A cross-sectional comparative study, involving 320 glaucoma patients and controls. Ocular Surface Disease Index (OSDI) symptoms score and Schirmer, tear breakup time and corneal staining tests were used to assess dry eye disease. Data was analyzed using SPSS version 24 software; p-value less than 0.05 was considered as statistically significant. Results Among the 160 study glaucoma patients, the mean duration of topical hypotensive medication use was 5.2 ± 5.21 years (range, 4 months - 32 years). Mild to severe level of OSDI score was found in 122 (76%) glaucoma patients and in 137 (86%) controls (p = 0.033). Mild to sever abnormal clinical tests in the glaucoma patients and control, respectively, were 106 (66%) vs 80 (50%) corneal staining (p = 0.045), 79 (49%) vs 72 (45%) TBUT (p = 0.021), and 91 (57%) vs 83 (52%) Schirmer test (p = 0.242). Test results at the level of sever: 2 (1%) vs 0 (0%) corneal staining, 50 (31%) vs 39 (24%) TBUT and 65 (41%) vs 60 (38%) Schirmer test in the glaucoma patents and controls, respectively. Corneal staining and TBUT had correlation with the number of drugs (p = 0.004 and 0.031, respectively), and more relationship of the two tests with total number of drops applied per day (p = 0.01 and p <  0.001, respectively). Patients on pilocarpine and timolol had more corneal staining and lower TBUT [(p = 0.011 and p <  0.001) and (p = 0.04 and 0.012), respectively]. Conclusions The study has identified glaucoma patients to be more affected by dry eye disease than non-glaucoma patients, and presence of significantly lower TBUT and higher corneal staining in the glaucoma patients on multidrops and multidose per day. We recommend consideration of evaluation and management of DED for glaucoma patients on multidrops and multidose hypotensive medications.

Influence of Carteolol and Timolol on IOP and Visual Fields in Glaucoma: A Multi-Center, Double-Masked, Prospective Study

1992 ◽  
Vol 2 (4) ◽  
pp. 169-174 ◽  
Author(s):  
J. Flammer ◽  
Y. Kitazawa ◽  
L. Bonomi ◽  
B. Mills ◽  
M. Fsadni ◽  
...  
Keyword(s):  
Visual Field ◽  
Prospective Study ◽  
Beta Blockers ◽  
Visual Fields ◽  
Visual Field Defects ◽  
Eye Drops ◽  
Treatment Groups ◽  
Visual Field Damage ◽  
One Year ◽  
Field Defects

The influences of Carteolol and Timolol eye drops on intraocular pressure (IOP) and visual fields were compared in a multi-center, double-masked, prospective study. Two-hundred and forty eyes of 120 patients were initially included in the study, and 142 eyes of 72 patients fulfilled all the criteria for final statistical analysis. Both drugs significantly reduced IOP. The visual fields in both treatment groups did not change during one year of treatment. In both groups some patients improved slightly, and others deteriorated slightly. This indicates that locally applied beta-blockers may efficiently stop further progression of visual field defects in cases with increased IOP and early visual field damage. There was no difference between Carteolol and Timolol in this regard. The side effects were minimal, and there were no differences in their frequency or intensity in the two treatment groups.

scholarly journals The Effect of Long-Term Use of an Eyewash Solution on the Ocular Surface Mucin Layer

2019 ◽  
Vol 20 (20) ◽  
pp. 5078 ◽  
Author(s):  
Hiroyuki Yazu ◽  
Naoyuki Kozuki ◽  
Murat Dogru ◽  
Ayako Shibasaki ◽  
Hiroshi Fujishima
Keyword(s):  
Ocular Surface ◽  
Periodic Acid ◽  
Tear Film ◽  
Periodic Acid Schiff ◽  
Dry Eyes ◽  
Staining Score ◽  
Related Quality ◽  
Pas Staining ◽  
Mucin Layer ◽  
A Prospective Study

The use of eyewash solutions in Japan, especially in patients with allergic conjunctivitis and contact lens wearers, has been increasing. Our aim was to investigate how the use of preservative-free eyewash solution in healthy eyes for one month affects corneal safety and ocular surface mucin. We analyzed 42 eyes of 21 individuals (17 males, four females; mean age: 36.1 ± 7.4 years) without ocular allergies, dry eyes, or other ocular diseases through a prospective study. Eyes were randomized to a wash group (group one) and a nonwash follow up group (group two). We evaluated the dry eye-related quality-of-life score (DEQS), tear film breakup time (TBUT), fluorescein staining score, mRNA expression of MUC5AC and MUC16, MUC16 immunohistochemistry, and MUC5AC periodic acid Schiff (PAS) staining. There was a significant decrease in DEQS scores after one month of eyewash use (p < 0.05). There were no significant differences in other evaluation items that were analyzed (all p > 0.05). Furthermore, no significant differences were observed between group one and group two in all endpoints (all p > 0.05). The results suggest that one month use of a nonpreserved eyewash solution has no detrimental effects on the tear film and the ocular surface mucins.

scholarly journals Management Of Recent Elbow Dislocations: Functional Treatment Versus Immobilization; A Prospective Study About 60 Cases

2017 ◽  
Vol 11 (1) ◽  
pp. 452-459 ◽  
Author(s):  
Ndeye Fatou Coulibaly ◽  
Niane Mouhamadou Moustapha ◽  
Hamadi Hadji Djoumoi ◽  
Sarr Lamine ◽  
Gueye Alioune Badara ◽  
...  
Keyword(s):  
Prospective Study ◽  
Elbow Dislocation ◽  
Early Mobilization ◽  
Functional Results ◽  
Functional Treatment ◽  
Functional Rehabilitation ◽  
Dislocation Reduction ◽  
Group 3 ◽  
Group 2 ◽  
A Prospective Study

Objective: To determine our therapeutic posture trough a comparison of functional treatment results versus immobilization in two different periods. Introduction: For years, the treatment of recent elbow dislocations consisted of reduction and immobilization during 21 days. Given the frequency of stiffness other methods have been tried out. Method: A prospective study was carried out from January 2010 to December 2014. Sixty patients averaging 28.3 years of age underwent elbow dislocation reduction. They were categorized into three separate groups. Patients in the first group had their elbow immobilized for 21 days whereas Group 2 patients were immobilized for 10 days. Group 3 patients were applied a functional treatment followed by a functional rehabilitation. Patients were evaluated according to the Mayo Clinic Elbow Performance Index and the results analyzed with statistical software (SPSS, version 18). Results: During the first month, the functional results of the patients were excellent and good in 19%, 94.7% and 90% respectively for Groups 1, 2 and 3. The pain was intense (10 on the visual analogue scale) in group 3 associated with swelling. At day 90, the results of the patients in Groups 2 and 3 were excellent in 100% of the cases versus 90% for Group 1. At 6 months, all the results were the same. We have not noted any instability, or recurrence or periarticular ossification in our patients. Conclusion: The treatment of stable elbow dislocations remains orthopedic. The risk of instability and pain motivates a short 10-day immobilization period followed by early mobilization.

Application of autologous serum eye drops after pterygium surgery: a prospective study

2018 ◽  
Vol 256 (10) ◽  
pp. 1939-1943 ◽  
Author(s):  
Sabahattin Sul ◽  
Safak Korkmaz ◽  
Goksu Alacamli ◽  
Pelin Ozyol ◽  
Erhan Ozyol
Keyword(s):  
Prospective Study ◽  
Autologous Serum ◽  
Eye Drops ◽  
Pterygium Surgery ◽  
A Prospective Study ◽  
Serum Eye Drops

scholarly journals Efficacy of eye drops containing crosslinked hyaluronic acid and CoQ10 in restoring ocular health exposed to chlorinated water

2020 ◽  
Vol 30 (3) ◽  
pp. 430-438
Author(s):  
Costanza Tredici ◽  
Romina Fasciani ◽  
Antonio Villano ◽  
Gloria Gambini ◽  
Aldo Caporossi
Keyword(s):  
Hyaluronic Acid ◽  
Ocular Surface ◽  
Prolonged Exposure ◽  
Ophthalmic Solution ◽  
Disease Index ◽  
Eye Drops ◽  
Ocular Surface Disease Index ◽  
Vitamin E Tpgs ◽  
Grading Scale ◽  
Breakup Time

Purpose: A prospective, open-label study in 20 professional swimmers evaluated the efficacy and safety of an ophthalmic solution containing crosslinked hyaluronic acid, coenzyme Q10, and vitamin E TPGS in releasing eye irritation and restoring ocular surface damages after prolonged exposure to chlorinated water. Methods: Individually, one eye was instilled with the ophthalmic solution and the other used as a comparator. Eye drops were self-administered three times a day for 2 months. Tear film breakup time (primary endpoint), Schirmer I test, beating of eyelashes/min, tear osmolarity, corneal and conjunctival staining with fluorescein, Ocular Surface Disease Index questionnaire, subject satisfaction, visual acuity (secondary endpoints), and Efron Grading Scale were evaluated at screening/baseline (V1), week 1 (V2), week 2 (V3), week 4 (V4), and week 8 (V5). Results: After 2 months, breakup time test significantly improved in the treated eyes (+1.67 s) compared to control (−3.00 s) ( p = 0.0002). Corneal and conjunctival surfaces of treated eyes recovered significantly compared to control eyes when assessed by fluorescein staining ( p < 0.0001), Ocular Surface Disease Index ( p < 0.05), and visual analog scale ( p = 0.0348) scores. Improvements were also observed with Schirmer I test, beating of eyelashes, and tear osmolarity, despite without statistical significance. Efron Grading Scale was consistent with the other tests. The ocular tolerability was excellent. Conclusion: The adequate combination of crosslinked hyaluronic acid, coenzyme Q10, and vitamin E TPGS, contained in the ophthalmic solution VisuXL®, has been shown to protect ocular surface from potential damages originating from prolonged exposure to chlorinated water. VisuXL may represent a compelling treatment in other situations beyond dry eye syndrome.

Sign in / Sign up

Export Citation Format

Share Document